Lilly to Acquire AtaiBeckley for Up to $3.8 Billion

Eli Lilly and Co (LLY) has agreed to acquire clinical-stage biotechnology company AtaiBeckley Inc (ATAI) in a deal valued at up to approximately $3.8 billion, enhancing its neuroscience portfolio with investigational therapies targeting treatment-resistant depression.

By Proactive Thu, July 16, 2026 at 3:41 PM GMT+3 3 min read · Yahoo Finance · July 16, 2026, 12:41 UTC

Lilly to Acquire AtaiBeckley for Up to $3.8 Billion

Tickers: $ATAI $LLY

Topics: biotechnology depression_therapies mental_health_treatment

Read the full article at Yahoo Finance

More World news

Analyst Ming-Chi Kuo Suggests Nvidia CEO Resignation May Have Limited Near-Term Stock Impact Seeking Alpha · November 12, 2026, 16:53 UTC
Solo Brands Lowers Net Sales Outlook While Projecting 2026 Adjusted EBITDA Growth Seeking Alpha · November 12, 2026, 16:50 UTC
EyePoint Pharmaceuticals Announces Strategic Shift to DURAVYU DME Following Phase III Wet AMD Trial Failures Seeking Alpha · November 12, 2026, 16:50 UTC
Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC